Alemtuzumab significantly improves posterior fossa syndrome presented as a relapse of multiple sclerosis

Mult Scler Relat Disord. 2020 Feb:38:101518. doi: 10.1016/j.msard.2019.101518. Epub 2019 Nov 12.

Abstract

Background: Posterior fossa syndrome (PFS) is a rare manifestation of ponto-mesencephalic lesions frequently reported in post-surgical pediatric tumors, rarely described as a consequence of vascular, infective or inflammatory lesions.

Objective: The aim of this article is to report the clinical and neuroradiological characteristics of a patient with an acute PFS presentation as a relapse in relapsing-remitting MS, significantly responsive to Alemtuzumab treatment.

Case report: 24-year-old patient affected by multiple sclerosis developed motor-cognitive and behavioral syndrome related to an extensive ponto-mesencephalic lesion under Fingolimod treatment.

Conclusion: Our case highlights the significant and rapid effect of Alemtuzumab therapy on both cognitive and motor symptoms occurring during a MS relapse with atypical neuroradiological localization.

Keywords: Alemtuzumab; Brainstem; Multiple sclerosis; Posterior fossa syndrome; Relapse.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Alemtuzumab / administration & dosage
  • Alemtuzumab / pharmacology*
  • Behavioral Symptoms / drug therapy
  • Behavioral Symptoms / etiology*
  • Behavioral Symptoms / physiopathology
  • Brain Diseases / drug therapy
  • Brain Diseases / etiology*
  • Brain Diseases / pathology
  • Brain Diseases / physiopathology
  • Brain Stem / pathology
  • Cognitive Dysfunction / drug therapy
  • Cognitive Dysfunction / etiology*
  • Cognitive Dysfunction / physiopathology
  • Fingolimod Hydrochloride / administration & dosage
  • Humans
  • Immunologic Factors / administration & dosage
  • Immunologic Factors / pharmacology*
  • Magnetic Resonance Imaging
  • Multiple Sclerosis, Relapsing-Remitting / complications*
  • Multiple Sclerosis, Relapsing-Remitting / drug therapy*
  • Mutism / drug therapy
  • Mutism / etiology*
  • Mutism / physiopathology
  • Recurrence
  • White Matter / pathology
  • Young Adult

Substances

  • Immunologic Factors
  • Alemtuzumab
  • Fingolimod Hydrochloride